fda glp-1 compounding enforcement september 2025 Beyond the Headlines: Warning Letters to Compounders What Patients Need to Know

Using plasma concentrations uncorrected for endogenous levocarnitine, the mean distribution half-life was 0.585 hours and the mean apparent terminal elimination half-life was 17.4 hours

Czerninski R, Zini A, Sgan-Cohen HD

As per the regulators Complete Response Letter, the FDA asked for additional evidence to confirm the efficacy and safety of glepaglutide at its proposed dose and recommended that Zealand run another clinical trial to generate these data

Gobburu et al., 1999)

High-risk individuals may receive more long-term cardiovascular protection if GLP-1 RAs are initiated earlier

M1M5, muscarinic acetylcholine receptor subtypes 15